The Pharmagellan Guide to Biotech Forecasting and Valuation - Softcover

David MD PhD, Frank S.; Robey PhD, Seth; Matthews MD, Andrew

 
9780998407500: The Pharmagellan Guide to Biotech Forecasting and Valuation
Softcover
ISBN 10: 099840750X ISBN 13: 9780998407500
Publisher: Pharmagellan, 2017

Synopsis

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser—or aspire to be one—then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs.

THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.


• Vetted benchmarks for key drivers of income, expenses, and valuation.
• Proprietary analyses by Pharmagellan's experienced consulting team.
• More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.

Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.

"synopsis" may belong to another edition of this title.

About the Author

Frank S. David, MD, PhD, is the founder and managing director of the biotech consultancy Pharmagellan (www.pharmagellan.com), an academic researcher and author on life sciences R&D, commercialization, and strategy, and a blogger about biomedical innovation at Forbes.com. He also maintains an active presence on Twitter (@Frank_S_David). Seth Robey, PhD, and Andrew Matthews, MD, are former and current associate consultants, respectively, at Pharmagellan.

"About this title" may belong to another edition of this title.

Publisher
Pharmagellan
Publication date
2017
Language
English
ISBN 10 
099840750X
ISBN 13 
9780998407500
Binding
Paperback
Illustrator
Clifton Denise
Edition number
1
Number of pages
138
Editor
Simison Robert, Cutchlow Tracy